RPS30B Antibody

What is the target of RPS30B antibody and what are its primary cellular functions?

RPS30B antibody targets the 40S ribosomal protein S30, which is a component of the 40S ribosomal subunit. Traditionally associated with ribosomal biogenesis, assembly, and translation, RPS30 contributes to the assembly and function of 40S ribosomal subunits. Recent evidence has highlighted extra-ribosomal functions of ribosomal proteins, including potential roles in tumor progression or suppression and immune surveillance. RPS30 is encoded by the FAU gene and synthesized as a fusion protein with the ubiquitin-like protein FUBI. Beyond its canonical role in protein synthesis, RPS30 may have pro-apoptotic activity, suggesting its involvement in programmed cell death pathways .

How is RPS30 expression regulated in normal versus cancer tissues?

Similar to other ribosomal proteins like RPL29, RPLP0, and RPS3, RPS30 expression can vary substantially among different cell lines and tissue types. Studies have shown heterogeneous expression of S30 in panels of human cancer cell lines. While this variation doesn't appear to affect the biogenesis or composition of the ribosome, it may be related to extraribosomal functions of S30 . The differential expression of ribosomal proteins is observed in a wide spectrum of cancers, suggesting that S30 expression patterns could potentially serve as biomarkers or therapeutic targets, similar to other ribosomal proteins that are upregulated in specific cancer types .

What is the relationship between FAU and RPS30B antibodies?

FAU (Finkel-Biskis-Reilly murine sarcoma virus ubiquitously expressed) is the gene that encodes the ubiquitin-like FUBI-ribosomal protein S30 fusion protein. Therefore, antibodies labeled as anti-FAU and anti-RPS30B target the same fusion protein product. The protein is synthesized as a fusion protein that undergoes post-translational processing to yield the ubiquitin-like protein FUBI and the ribosomal protein S30. When selecting antibodies for research, it's important to understand which domain of the fusion protein is recognized by the antibody (FUBI domain, S30 domain, or the junction region), as this will affect the experimental applications and interpretations .

Which applications are most suitable for RPS30B antibody research?

Based on available validation data, RPS30B antibodies are suitable for several common applications:

• Immunohistochemistry on paraffin-embedded tissues (IHC-P): Successfully used to detect S30 in human colon cancer and endometrial cancer tissues

• Immunocytochemistry/Immunofluorescence (ICC/IF): Validated in HeLa cells to detect subcellular localization

• Western blotting (WB): Useful for detecting S30 protein levels in cell and tissue lysates

While not explicitly mentioned in the search results, these antibodies might also be applicable for immunoprecipitation (IP) and chromatin immunoprecipitation (ChIP) experiments when investigating protein-protein or protein-DNA interactions, though validation would be necessary .

How should RPS30B antibody specificity be validated?

Ribosomal protein antibody specificity can be validated through multiple complementary approaches:

• siRNA knockdown validation: Similar to validations of other ribosomal protein antibodies (RPS28, RPL5, RPL29, RPLP0, RPS3), siRNA-mediated knockdown of RPS30 should result in reduced signal in western blot analysis compared to non-specific scrambled siRNA controls and untransfected cells.

• Genetic modification strategies: Techniques such as CRISPR-Cas9 to reduce or eliminate target expression can demonstrate antibody specificity.

• Recombinant protein controls: Using purified recombinant RPS30 protein as a positive control to confirm antibody binding specificity.

• Immunoblotting pattern: Confirmation that the antibody detects a single band of the expected molecular weight in western blot analyses of purified ribosomes .

What are the recommended protocols for detecting RPS30 in human cancer tissues?

For immunohistochemistry on paraffin-embedded human cancer tissues:

• Sample preparation: Fix tissues in formalin and embed in paraffin; cut sections at 4-5 μm thickness

• Deparaffinization: Use xylene followed by rehydration through graded alcohols

• Antigen retrieval: Typically heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Blocking: Block endogenous peroxidase activity with hydrogen peroxide and non-specific binding with normal serum

• Primary antibody incubation: Use RPS30B antibody at approximately 1/100 dilution (optimize for specific antibody)

• Detection system: Apply appropriate secondary antibody followed by chromogen development

• Counterstaining: Use hematoxylin for nuclear visualization

• Mounting: Apply appropriate mounting medium

This protocol has been successfully used for detecting RPS30 in human colon cancer and endometrial cancer tissues .

How should researchers interpret heterogeneous expression of RPS30 in experimental models?

When analyzing heterogeneous expression of RPS30 across different experimental models or cancer cell lines, researchers should consider:

• Extraribosomal functions: Variations in S30 expression that don't affect ribosome biogenesis or composition likely relate to extraribosomal functions rather than protein synthesis capacity.

• Correlation with phenotype: Assess whether expression levels correlate with specific cellular phenotypes such as proliferation rate, apoptosis resistance, or metastatic potential.

• Context within ribosomal protein network: Compare expression patterns with other ribosomal proteins (e.g., S11) that show similar heterogeneity to identify potential functional relationships.

• Subcellular localization: Analyze both nuclear and cytoplasmic distribution, as non-canonical functions may be associated with specific compartmentalization.

• Relation to p53 pathway: Many ribosomal proteins interact with the p53 pathway; investigate whether S30 expression correlates with p53 status or activity in your models .

What are the implications of RPS30 mutations or altered expression in cancer research?

Based on patterns observed with other ribosomal proteins:

• Tumor suppressor vs. oncogenic roles: Similar to how RPL5 mutations occur in various cancers (glioblastomas, breast cancers, melanomas) and RPL11 deletion shows susceptibility to lymphomagenesis, RPS30 alterations might have context-dependent roles in tumor biology.

• Biomarker potential: Differential expression across cancer types may provide diagnostic or prognostic value, similar to how RPL29 is upregulated in colon cancer and RPL3 in colorectal carcinomas.

• Pathway interactions: As with RPL29's modulation of p21 and p53 pathways, RPS30 alterations may affect key signaling pathways involved in cell cycle control and apoptosis.

• Therapeutic targeting: Understanding RPS30's role in cancer cells could potentially reveal novel therapeutic vulnerabilities, particularly if cancer cells become dependent on its expression .

How does RPS30 compare with other ribosomal proteins in cancer research applications?

When comparing RPS30 with other ribosomal proteins:

This comparative analysis helps researchers decide which ribosomal proteins might be most relevant to their specific cancer research questions and experimental systems .

What methodological approaches can distinguish between canonical and extraribosomal functions of RPS30?

To differentiate between canonical ribosomal functions and extraribosomal roles of RPS30:

• Subcellular fractionation: Isolate different cellular compartments (cytoplasm, nucleus, mitochondria) and analyze RPS30 distribution using the antibody in western blotting to identify non-ribosomal pools.

• Polysome profiling: Separate ribosomal subunits, monosomes, and polysomes on sucrose gradients, then analyze the distribution of RPS30 to determine association with translating ribosomes versus free protein.

• Proximity labeling: Use BioID or APEX2 fused to RPS30 to identify proximity interactors, comparing results to known ribosomal protein interaction networks to identify unique partners.

• Partial knockdown: Titrate siRNA to achieve partial knockdown and determine differential effects on translation versus potential extraribosomal functions.

• Domain-specific mutations: Introduce mutations that specifically affect either ribosome incorporation or extraribosomal interactions to parse functions .

How can RPS30B antibodies be used in studies of cancer progression mechanisms?

RPS30B antibodies can contribute to cancer research through:

• Tissue microarray analysis: Screen multiple cancer tissues to establish expression patterns across cancer types and stages, correlating with clinical outcomes to assess prognostic value.

• Co-immunoprecipitation studies: Identify cancer-specific interaction partners in different cancer models that might explain extraribosomal functions.

• Chromatin association: Investigate potential direct or indirect roles in gene regulation through ChIP experiments if RPS30 shows nuclear localization.

• Response to therapy: Monitor changes in RPS30 expression or localization following treatment with chemotherapeutic agents or targeted therapies.

• Post-translational modifications: Use phospho-specific or other modification-specific antibodies (if available) to determine how cancer-associated signaling pathways might regulate RPS30 function .

What experimental controls are critical when studying RPS30 in complex with other ribosomal proteins?

When investigating RPS30 in the context of ribosomal complexes:

• Ribosome assembly controls: Include markers for both 40S (where RPS30 resides) and 60S subunits to ensure proper ribosome assembly is maintained during experimental manipulations.

• Translation activity measurements: Complement protein expression data with functional assays of translation (polysome profiling, puromycin incorporation) to correlate RPS30 levels with ribosomal function.

• Specificity controls: Use siRNA knockdown of RPS30 to verify antibody specificity in complex samples where multiple ribosomal proteins are present.

• Cross-reactivity testing: Ensure the RPS30B antibody doesn't cross-react with other ribosomal proteins, particularly those with similar molecular weights, by testing on purified ribosomes from knockdown cells.

• Antibody combinations: When using multiple ribosomal protein antibodies simultaneously (e.g., for co-localization studies), verify that secondary antibodies don't cross-react and that signals can be distinguished .

What are common challenges when using RPS30B antibodies, and how can they be addressed?

Researchers commonly encounter these challenges when working with ribosomal protein antibodies:

• Background signal: Optimize blocking conditions (try different blocking agents like BSA, normal serum, or commercial blockers) and increase washing stringency (add 0.1-0.3% Triton X-100 or increase NaCl concentration in wash buffers).

• Epitope masking: If the epitope is obscured in certain contexts, try different antigen retrieval methods for IHC or different sample preparation techniques (native vs. denaturing conditions).

• Antibody specificity: Validate using positive controls (tissues known to express high levels of RPS30) and negative controls (knockdown samples or tissues with low expression).

• Fixation artifacts: Test different fixation protocols as overfixation can mask epitopes, while underfixation can compromise tissue morphology.

• Subcellular localization discrepancies: Nuclear vs. cytoplasmic staining patterns may vary based on fixation, permeabilization, and antibody clone; compare results using different fixation methods .

How can researchers optimize experimental conditions for RPS30B antibody in different tissue types?

For optimal results across diverse tissue types:

• Antibody titration: Perform a dilution series (e.g., 1:50, 1:100, 1:200, 1:500) for each new tissue type to identify the optimal concentration that maximizes specific signal while minimizing background.

• Antigen retrieval optimization: Compare heat-induced epitope retrieval using different buffers (citrate pH 6.0, EDTA pH 9.0, Tris-EDTA pH 8.0) and methods (microwave, pressure cooker, water bath).

• Incubation conditions: Test different incubation times and temperatures (overnight at 4°C vs. 1-2 hours at room temperature) to enhance specific binding.

• Detection system sensitivity: For tissues with low expression, switch to more sensitive detection methods like tyramide signal amplification or polymer-based detection systems.

• Tissue-specific controls: Include tissue-matched positive and negative controls processed identically to experimental samples to account for tissue-specific factors affecting antibody performance .

How should researchers approach contradictory data when comparing RPS30 and other ribosomal protein antibodies?

When facing contradictory results:

• Antibody validation comparison: Re-validate all antibodies using siRNA knockdown or other methods to ensure specificity in your experimental system.

• Epitope mapping: Determine which region of the target protein each antibody recognizes, as different antibodies may detect different isoforms or processed forms.

• Technical vs. biological variability: Distinguish between technical artifacts (batch effects, protocol differences) and true biological variability by repeating experiments with standardized protocols.

• Sample preparation effects: Assess whether differences arise from sample preparation methods that might differentially affect epitope availability.

• Contextual regulation: Consider that ribosomal proteins may show context-dependent regulation where relationships between different proteins vary by cell type or condition.

• Literature reconciliation: Conduct thorough literature review to identify methodological differences that might explain contradictions and design experiments to directly test competing hypotheses .